STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
137
13F, latest reported quarter
What the filings say about BNTX
Insiders, 180 days
-$84.2M net sold
1 seller · 100% of sales under a 10b5-1 plan
Congress, 1 year
No trades
Last one: sale, 2025-08-07
Planned sales (Form 144), 90 days
$89.1M
1 notice
BioNTech insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, BioNTech SE insiders sold a net $84.2M of stock across 27 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Foreign private issuer: most of its insiders are exempt from SEC Form 4, but some still file it; those filings are listed below, and the record may be incomplete.
25 earlier Form 4 trades (code P or S) here by this insider (25 sales), the last on Oct 8, 2026.
No other insider sold within 30 days.
137 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Sahin Ugur sold about $3.5M of BNTX under a 10b5-1 plan on Oct 9, 2026; 137 funds added in the latest 13F quarter.
24 earlier Form 4 trades (code P or S) here by this insider (24 sales), the last on Oct 7, 2026.
The trade is 74.6% of the 36,209 shares held after it.
No other insider sold within 30 days.
137 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Sahin Ugur sold about $2.5M of BNTX under a 10b5-1 plan on Oct 8, 2026; 137 funds added in the latest 13F quarter.
23 earlier Form 4 trades (code P or S) here by this insider (23 sales), the last on Oct 6, 2026.
The trade is 38.0% of the 63,209 shares held after it.
No other insider sold within 30 days.
137 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Sahin Ugur sold about $2.3M of BNTX under a 10b5-1 plan on Oct 7, 2026; 137 funds added in the latest 13F quarter.
22 earlier Form 4 trades (code P or S) here by this insider (22 sales), the last on Oct 5, 2026.
The trade is 24.1% of the 87,209 shares held after it.
No other insider sold within 30 days.
137 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Sahin Ugur sold about $2.0M of BNTX under a 10b5-1 plan on Oct 6, 2026; 137 funds added in the latest 13F quarter.
21 earlier Form 4 trades (code P or S) here by this insider (21 sales), the last on Oct 2, 2026.
The trade is 66.5% of the 108,209 shares held after it.
No other insider sold within 30 days.
137 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Sahin Ugur sold about $7.0M of BNTX under a 10b5-1 plan on Oct 5, 2026, the largest insider sale at the company on our record; 137 funds added in the latest 13F quarter.
27 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Nobody has filed for crossing 5%. That is a fact, not missing data.
BNTX planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Medine GmbH
Filed 2026-09-03
$89.1M
BNTX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Genomics Immunology and Healthcare ETF
$7.1M position · as of 2026-07-31
3.7%
Global X Genomics & Biotechnology ETF
$1.9M position · as of 2026-05-31
3.4%
First Trust NYSE Arca Biotechnology Index Fund
$73.9M position · as of 2026-06-30
2.6%
VanEck Biotech ETF
$7.7M position · as of 2026-06-30
1.9%
PROFUND VP EUROPE 30
$310.8K position · as of 2026-06-30
1.8%
Franklin International Growth Fund
$9.6M position · as of 2026-07-31
1.6%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
74 registered trials, 32 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
15
Phase 1
6 active
14
Phase 2
7 active
13
Phase 3
5 active
2
Phase 4
1 active
1
Not applicable
0 active
29
Multi-phase
13 active
What changed recently
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
2026-10-17 · Completion moved 2026-07-31 → 2026-09-22
Phase 3
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
2026-10-17 · Active Not Recruiting → Completed
Phase 3
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemothera
2026-10-15 · Completion moved 2028-12 → 2029-04
Phase 3
A Study of COVID-19 Vaccine(s) in Children and Adults
2026-09-29 · Completion moved 2027-04-20 → 2027-04-21
Phase 3
A Study of COVID-19 Vaccine(s) in Children and Adults
2026-09-29 · Not Yet Recruiting → Recruiting
Phase 3
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced
2026-09-10 · Completion moved 2028-06 → 2031-04
PHASE1,PHASE2
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $84.2M sold by insiders over 180 days, 137 funds added last quarter, $89.1M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
BNTX ranks highest on institutional and government (79th percentile) and risk and compliance (73rd), and lowest on insider conviction (1st), among Pharma & Biotech peers.
Insider conviction
0
Inputs
Net Form 4 buying (codes P and S), 180dno Form 4 purchase or sale (code P or S) in 180 days
Insider buyers, 180d0 · 0 pct, sector of 438
Institutional and government
79
Inputs
Funds adding, latest quarter137 · 79 pct, sector of 698
Congress net buyers, 365dno Congress trades in 365 days
Federal contracts, 180dno federal contracts in 180 days
Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
73
Inputs
Short interest, % of float+2.1% · 73 pct, sector of 816
Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Profitability, Financial health, Growth, US patents
Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
Financial health needs 1 of 2 inputs, 0 present: no debt line filed
Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet
3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
BNTX filings, in plain words
Are BioNTech insiders buying or selling BNTX?
In the 180 days to 2026-10-28, BioNTech insiders were net sellers, a net $84.2M across purchases and sales reported on Form 4, by 1 seller.
Have members of Congress traded BNTX?
Yes, but not in the year to 2026-10-28; the latest on record is a sale by Valerie Hoyle dated 2025-08-07.
Are there planned insider sales of BNTX?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $89.1M of stock; the latest, by Medine GmbH, was filed 2026-09-03.
Read the full summary
In the 180 days to 2026-10-28, BioNTech insiders were net sellers of BNTX, a net $84.2M across purchases and sales reported on Form 4 by 1 seller. Most of that figure, $84.2M, came from a holder of 10% or more rather than an officer or director. 100% of the 26 insider sales were made under a pre-arranged Rule 10b5-1 plan, so most selling was scheduled in advance. Members of Congress have disclosed trades in BNTX, none in the last year; the latest on record is a sale by Valerie Hoyle dated 2025-08-07. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $89.1M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
No password to create and no card required. We store your email address, your watchlist and your preferences, nothing else.
PRIVACY & COOKIES
We track filings, not you.
Essential cookies keep you signed in and remember this choice.
Google Analytics 4 and Microsoft Clarity load only if you allow them here; they
count visits and record how pages are used. We run no advertising and never sell
data. Details in the privacy policy. Change this any time
via "Cookie settings" in the footer.
